Invitation to the EBAC-accredited satellite symposium 'Navigating therapeutic approaches in HCM: Unravelling recent evidence', at ESC HF 2024, Lisbon, Portugal.
For more information, please visit the ESC website.
Learning Objectives
Educational Objectives
- Recognize clinical scenarios indicative of the need for an HCM-specific therapeutic approach
- Evaluate the most recent clinical data on the application of myosin inhibitors in treating HCM among patients with heart failure
- Deliberate on the supporting evidence and focused recommendations outlined in recently published guidelines concerning hypertrophic cardiomyopathy
Agenda
Chair: Roberto Barriales-Villa, MD, PhD – A Coruña, Spain
12:30 – 12:40 Welcome and introduction - Roberto Barriales-Villa, MD, PhD – A Coruña, Spain
12:40 – 12:50 Epidemiology and clinical features of hypertrophic cardiomyopathy - Perry Elliott, MD, PhD – London, United Kingdom
12:50 – 13:00 Cardiac physiology and pathophysiology of HCM, including peak oxygen Uptake (pVO2) - Ahmad Masri, MD – Portland, OR, USA
13:00 - 13:10 Myosin inhibitors: recent clinical data and applications in HCM and HF - Caroline Coats, MD – Glasgow, United Kingdom
13:10 – 13:20 Precision medicine and focused recommendations in HCM guidelines - Ahmad Masri, MD – Portland, OR, USA / Roberto Barriales-Villa, MD, PhD – A Coruña, Spain
13:20 – 13:30 Panel discussion and Q&A - All faculty
CME Accreditation
This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
Funding
This symposium is supported by an unrestricted educational grant from Cytokinetics.
